Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. Toronto Stock Exchange
  5. Knight Therapeutics Inc.
  6. Financials
    GUD   CA4990531069

KNIGHT THERAPEUTICS INC.

(GUD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Valuation
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Capitalization1 1 0981 028696647--
Entreprise Value (EV)1 4091 028696647647647
P/E ratio 45,5x75,8x16,8x26,5x45,8x13,9x
Yield ------
Capitalization / Revenue 87,9x21,7x3,49x2,62x2,24x2,07x
EV / Revenue 87,9x21,7x3,49x2,62x2,24x2,07x
EV / EBITDA -285x-111x41,3x15,1x11,7x11,2x
Price to Book 1,07x1,27x0,79x0,74x0,72x0,67x
Nbr of stocks (in thousands) 142 844135 629130 035122 073--
Reference price (CAD) 7,697,585,355,305,305,30
Announcement Date 03/14/201903/30/202003/25/2021---
1 CAD in Million
Estimates
Income Statement Evolution (Annual data)
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net sales1 12,547,5200247289312
EBITDA1 -3,85-9,2416,842,755,357,6
Operating profit (EBIT)1 -5,78--4,4735,757,8-
Operating Margin -46,3%--2,24%14,5%20,0%-
Pre-Tax Profit (EBT)1 29,522,832,119,635,560,1
Net income1 24,114,542,122,811,4-
Net margin 193%30,6%21,1%9,23%3,96%-
EPS2 0,170,100,320,200,120,38
Dividend per Share ------
Announcement Date 03/14/201903/30/202003/25/2021---
1 CAD in Million
2 CAD
Income Statement Evolution (Quarterly data)
Fiscal Period: December 2021 Q1 2021 Q2 2021 Q3 2021 Q4 2022 Q1 2022 Q2
Net sales1 46,165,873,361,867,971,9
EBITDA1 5,589,4017,310,815,414,6
Operating profit (EBIT)1 3,077,6515,29,76--
Operating Margin 6,66%11,6%20,8%15,8%--
Pre-Tax Profit (EBT)1 4,4326,6-9,89-1,46--
Net income1 3,5629,0-8,59-1,37--
Net margin 7,72%44,1%-11,7%-2,21%--
EPS2 0,030,23-0,070,000,020,02
Dividend per Share ------
Announcement Date 05/14/202108/13/202111/11/2021---
1 CAD in Million
2 CAD
Previous periodNext period
Balance Sheet Analysis
Fiscal Period: December 2018 2019 2020 2021 2022 2023
Net Debt ------
Net Cash position 690-----
Leverage (Debt / EBITDA) 179x-----
Free Cash Flow1 -5,944,49-17,648,040,0-
ROE (Net Profit / Equities) 2,38%1,58%4,96%4,40%3,10%5,00%
Shareholders' equity1 1 011920848518369-
ROA (Net Profit / Asset) 2,34%-----
Assets1 1 029-----
Book Value Per Share2 7,215,996,827,127,387,91
Cash Flow per Share2 -0,040,03--1,210,530,88
Capex1 0,200,115,380,43--
Capex / Sales 1,62%0,23%2,70%0,17%--
Announcement Date 03/14/201903/30/202003/25/2021---
1 CAD in Million
2 CAD
Key data
Capitalization (CAD) 646 987 933
Capitalization (USD) 505 933 635
Net sales (CAD) 199 519 000
Net sales (USD) 155 824 339
Number of employees 679
Sales / Employee (CAD) 293 842
Sales / Employee (USD) 229 491
Free-Float 83,5%
Free-Float capitalization (CAD) 540 337 706
Free-Float capitalization (USD) 422 534 959
Avg. Exchange 20 sessions (CAD) 2 503 988
Avg. Exchange 20 sessions (USD) 1 955 615
Average Daily Capital Traded 0,39%
EPS & Dividend
Year-on-year evolution of the PER